COCH

Envoy Medical, Inc. (COCH) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Envoy Medical is a hearing health company focused on developing fully implanted hearing solutions. The company's primary focus is the Acclaim CI, an investigational fully implanted cochlear implant currently in a pivotal clinical trial. The company also maintains the Esteem FI-AMEI, an FDA-approved fully implanted active middle ear implant, though commercial traction has been limited due to reimbursement challenges. The company is classified as a Smaller Reporting Company and an Emerging Growth Company.

Key Financial Metrics

Liquidity and Debt: As of March 31, 2026, the company held $25.3 million in cash. All outstanding related-party Term Loans were extinguished in August 2025. The company has significant warrant liabilities classified as liabilities on the balance sheet, totaling approximately $4.8 million ($3.8 million private, $0.9 million public, and $0.04 million forward purchase agreement).

Material Changes vs. Prior Period

• Capital Raise: In February 2026, the company completed a public offering (February 2026 Offering) raising net proceeds of approximately $27.8 million. This included the issuance of Class A Common Stock, pre-funded warrants, and Series A Warrants. This influx of capital significantly improved liquidity compared to the $3.7 million cash balance at the end of 2025.
• Revenue Decline: Net revenues decreased by 15.2% to $39,000, driven by minimal sales of the Esteem FI-AMEI and replacement components.
• Expense Increases:
  • R&D Expenses: Increased 32.5% to $3.6 million, primarily due to a 170.9% increase in clinical trial costs ($1.6 million) as the pivotal trial for the Acclaim CI progressed.
  • Cost of Goods Sold: Increased 38.5% to $313,000 due to higher scrap and material usage.
• Non-Operating Gains: The company recognized a $2.0 million gain from the change in fair value of private warrant liabilities, offsetting a portion of the operating loss. Conversely, there was a $390,000 loss on the change in fair value of publicly traded warrants.
• Interest Expense: Interest expense related to term loans dropped to zero as the debt was extinguished in the prior year.

Guidance, Outlook, and Risks

• Clinical Trial Status: The pivotal clinical trial for the Acclaim CI has enrolled all 56 patients. As of March 31, 2026, the first three patients have reached the 12-month follow-up evaluation. The company anticipates submitting a Premarket Approval (PMA) application to the FDA after all patients complete their 12-month visits.
• Regulatory Timeline: Management anticipates an FDA decision on the PMA application in the second half of 2027, potentially extending to the first half of 2028 if a panel review is requested.
• Liquidity Outlook: Management believes current cash balances, combined with potential proceeds from warrant exercises, are sufficient to fund operations through the second quarter of 2027. However, the filing includes a "substantial doubt" disclosure regarding the company's ability to continue as a going concern without additional financing.
• Internal Controls: The company disclosed that its disclosure controls and procedures were not effective as of March 31, 2026, due to material weaknesses in internal control over financial reporting, including limited accounting personnel and lack of formal risk assessment and IT controls.
• Legal Proceedings: The company is defending a lawsuit filed by Atlas Merchant Capital SPAC Fund I LP alleging improper prevention of share redemptions during the SPAC merger. The plaintiff seeks approximately $9.4 million in damages. The company believes the suit is meritless.

Key Facts for Investor Verification

• Capital Runway: Verify the sufficiency of the $25.3 million cash balance to fund the remainder of the Acclaim CI clinical trial and PMA submission without further dilution, given the "substantial doubt" going concern warning.
• Warrant Liability Volatility: Monitor the fair value of the $4.8 million in warrant liabilities, as fluctuations in stock price significantly impact reported net income/loss.
• Clinical Milestones: Track the 12-month follow-up completion for the remaining 53 patients in the pivotal trial, which is the prerequisite for PMA submission.
• Internal Control Remediation: Assess the progress of remediation plans for the material weaknesses in internal controls, which could impact future reporting reliability.
• Preferred Stock Dividends: Note the accrued unpaid dividends on Series A Preferred Stock ($3.3 million total accrued), which have priority over common stock in liquidation and accrue at 12% annually.